The purpose of this project is to gather the information and create the infrastructure needed to plan and carry out clinical trials for patients with deficient glycosylation of alpha-dystroglycan. These patients have muscular dystrophy, with or without multisystem involvement (the dystroglycanopathies). Thus far, mutafions in six genes (POMTl, P0MT2, POMGnTI, FKTN, FKRP, and LARGE) are known to result in dystroglycanopathies. There are several clinical subtypes, and these have overiapping phenotypes. The dystroglycanopathy population poses special challenges in thinking about treatment trials due to the wide range in clinical severity. In addition, the cognitive impairment seen in some of the subtypes limits patients'ability to cooperate with testing.
In Aim 1, we will recruit patients with suspected or proven dystroglycanopathies and define their clinical phenotypes using historical information, standardized functional tests, and muscle ultrasound. In cooperation with Core B, we will evaluate muscle biopsies, define patients'alpha-dystroglycan glycosylation status in cultured fibroblasts, and determine their genotype.
In Aim 2, we will follow patients with dystroglycanopathy longitudinally using a battery of potential clinical trial outcome measures. This will provide us with natural history information and determine optimal outcome measures for use in therapeutic trials.
In Aim 3, we will develop the infrastructure for a proposed clinical trial of corticosteroids, using the data collected in Aims 1 and 2 to guide trial design. Anecdotes and case reports suggest corticosteroids are beneficial in patients with the dystroglycanopathies. In this proposal, we will develop the patient cohort, outcome markers and infrastructure to test this hypothesis. We expect that the results of these three aims will prepare us to evaluate novel treatments for these rare forms of muscular dystrophy as they become available.
The dystroglycanopathies are a group of muscular dystrophies with a wide range of severity. This clinical spectrum presents special challenges in planning treatment trials for this population. In this proposal, we will collect data and create an infrastructure that will facilitate translation of possible treatments to clinical trials.
|Briggs, David C; Yoshida-Moriguchi, Takako; Zheng, Tianqing et al. (2016) Structural basis of laminin binding to the LARGE glycans on dystroglycan. Nat Chem Biol 12:810-4|
|de Greef, Jessica C; Hamlyn, Rebecca; Jensen, Braden S et al. (2016) Collagen VI deficiency reduces muscle pathology, but does not improve muscle function, in the Î³-sarcoglycan-null mouse. Hum Mol Genet 25:1357-69|
|Jerber, Julie; Zaki, Maha S; Al-Aama, Jumana Y et al. (2016) Biallelic Mutations in TMTC3, Encoding a Transmembrane and TPR-Containing Protein, Lead to Cobblestone Lissencephaly. Am J Hum Genet 99:1181-1189|
|Lawlor, Michael W; Beggs, Alan H; Buj-Bello, Ana et al. (2016) Skeletal Muscle Pathology in X-Linked Myotubular Myopathy: Review With Cross-Species Comparisons. J Neuropathol Exp Neurol 75:102-10|
|Praissman, Jeremy L; Willer, Tobias; Sheikh, M Osman et al. (2016) The functional O-mannose glycan on Î±-dystroglycan contains a phospho-ribitol primed for matriglycan addition. Elife 5:|
|Agre, Peter; Bertozzi, Carolyn; Bissell, Mina et al. (2016) Training the next generation of biomedical investigators in glycosciences. J Clin Invest 126:405-8|
|Turk, Rolf; Hsiao, Jordy J; Smits, Melinda M et al. (2016) Molecular Signatures of Membrane Protein Complexes Underlying Muscular Dystrophy. Mol Cell Proteomics 15:2169-85|
|Rader, Erik P; Turk, Rolf; Willer, Tobias et al. (2016) Role of dystroglycan in limiting contraction-induced injury to the sarcomeric cytoskeleton of mature skeletal muscle. Proc Natl Acad Sci U S A 113:10992-7|
|Jensen, Braden S; Willer, Tobias; Saade, Dimah N et al. (2015) GMPPB-Associated Dystroglycanopathy: Emerging Common Variants with Phenotype Correlation. Hum Mutat 36:1159-63|
|Luo, Sushan; Zhu, Wenhua; Yue, Dongyue et al. (2015) Muscle pathology and whole-body MRI in a polyglucosan myopathy associated with a novel glycogenin-1 mutation. Neuromuscul Disord 25:780-5|
Showing the most recent 10 out of 75 publications